Synthetic Control Subjects for Alzheimer's Disease Clinical Trials (AAIC 2019)

Objective: To develop a method to model disease progression that simulates detailed clinical data records for subjects in the control arms of Alzheimer's disease clinical trials. Methods: We used a robust data processing framework to build a machine learning dataset from a database of subjects in the control arms of a diverse set of 28 clinical trials on Alzheimer's disease. From this dataset, we selected 1908 subjects with 18-month trajectories of 44 variables and trained a model capable of simulating disease progression in 3-month intervals across all variables. Results: Based on a statistical analysis comparing data from actual and simulated subjects, the model generates accurate subject-level distributions across variables and through time. Focusing on a common clinical trial endpoint for Alzheimer's disease (ADAS-Cog), we show the model can predict disease progression as accurately as several supervised models. Our model also predicts the outcome of a clinical trial whose data are distinct from the training and test datasets. Conclusion: The ability to simulate dozens of clinical characteristics simultaneously is a powerful tool to model disease progression. Such models have useful applications for clinical trials, from analyzing control groups to supplementing real subject data in control arms.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Webinars

Part 3: Innovation in Clinical Research: AI-based Drug Development Tools and the Regulatory Landscape‍

Webinars

Part 2: Faster, More Efficient Trials: Novel Trial Designs using Digital Twins‍

Webinars

Part 1: AI, Digital Twins, and the Future of Clinical Research‍

Learn about how Digital Twins are created and how they are incorporated into clinical trials to increase power, accelerate timelines, and enable patient level insights.
Watch an overview of specific use cases for Digital Twins and learn how novel trial designs with Digital Twins enable smaller trials that maintain their power.
Watch a panel discussion on the regulatory landscape where experts share perspectives on the future of AI-based drug development tools like Digital Twins.